Relationship between outcome and cytogenetics, age immunophenotype, and type of treatment in 70 MPAL patients with follow-up information
| Feature . | Dead, N = 40 . | Median survival, mo (95% CI) . | Significance . |
|---|---|---|---|
| Children,* N = 27 | 8 | 139 (undefined) | P < .001 |
| Adults, N = 42 | 31 | 11 8.(5-13.5) | |
| Genetics | |||
| Ph+, N = 12 | 11 | 8 (2-14) | Ph+ vs all others, P = .002 |
| MLL, N = 6 | 2 | Undefined | |
| Complex, N = 21 | 9 | 47(undefined) | |
| Other, N = 19 | 10 | 30 (1-59) | |
| Normal, N = 7 | 3 | 139 (1-277) | |
| Not available, N = 12 | 5 | 3 (3-5) | |
| Immunophenotype | |||
| B + My, N = 39 | 23 | 13 (0-35) | P = .7 |
| T + My, N = 27 | 15 | 18 (0-55) | |
| T + B/B + T + My, N = 4 | 2 | Undefined | |
| Treatment: | |||
| ALL, N = 27 | 10 | 139 (8-270) | ALL vs AML/other, P = .003 |
| AML,N = 34 | 22 | 11 (8-14) | |
| Others, N = 6 | 5 | 3 (0-6) | |
| None/unknown, N = 3 | 3 |
| Feature . | Dead, N = 40 . | Median survival, mo (95% CI) . | Significance . |
|---|---|---|---|
| Children,* N = 27 | 8 | 139 (undefined) | P < .001 |
| Adults, N = 42 | 31 | 11 8.(5-13.5) | |
| Genetics | |||
| Ph+, N = 12 | 11 | 8 (2-14) | Ph+ vs all others, P = .002 |
| MLL, N = 6 | 2 | Undefined | |
| Complex, N = 21 | 9 | 47(undefined) | |
| Other, N = 19 | 10 | 30 (1-59) | |
| Normal, N = 7 | 3 | 139 (1-277) | |
| Not available, N = 12 | 5 | 3 (3-5) | |
| Immunophenotype | |||
| B + My, N = 39 | 23 | 13 (0-35) | P = .7 |
| T + My, N = 27 | 15 | 18 (0-55) | |
| T + B/B + T + My, N = 4 | 2 | Undefined | |
| Treatment: | |||
| ALL, N = 27 | 10 | 139 (8-270) | ALL vs AML/other, P = .003 |
| AML,N = 34 | 22 | 11 (8-14) | |
| Others, N = 6 | 5 | 3 (0-6) | |
| None/unknown, N = 3 | 3 |
MPAL indicates mixed-phenotype acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; and CI, confidence interval.
Age of 1 patient unknown.